Jump to navigation

Congo-Kinshasa

Ebola outbreak puts vaccine ambitions on trial

The UN’s warning about the lack of vaccines has turned a health emergency into a test of Africa’s stalled manufacturing plans

World Health Organization officials reported at least 139 suspected Ebola deaths on 21 May and said neither of the two candidate vaccines for the Bundibugyo species has yet reached clinical trials. That leaves the response reliant on containment measures and prompts more scrutiny on African Union- and European Union-backed plans that will take years to deliver meaningful vaccine production capacity on the continent.

The death toll from Ebola in Congo-Kinshasa is likely to spike sharply in the coming weeks, the WHO has warned. It is likely to be at least nine months before a vaccine against this strain of Ebola is ready.

The WHO is ranking the outbreak as an ‘international health emergency’ rather than an ‘epidemic’ the designation given to the 2014-2016 outbreak.

For now, the AU and other international organisations say there is only a low risk of the virus spreading. Congo-K has banned travel to Ituri province in the country’s north-east border with Uganda and South Sudan, where almost all of the cases have been reported.

But WHO advisor Dr Vasee Moorthy told journalists that neither of the two ‘candidate vaccines’ against the Bundibugyo species had got to the clinical trial phases.

As the new vaccine is under trial, demands will intensify to accelerate the continent’s vaccine production capacity (AC Vol 61 No 20, Paths out of the pandemic). For now, initiatives launched by the AU with the European Union to diversify supply chains and increase Africa’s vaccine production, will take at least another five years to start.

The AU targets 2040 for the continent to produce 60% of its own key vaccines. The EU’s Africa-focused Global Health Resilience Initiative, launched in mid-May, quotes the same timeline but is due to open an initial production facility in Cape Town in 2028.


Subscribe now and save 15% on a year’s subscription

Click the above to claim your 15% discount on your first Africa Confidential subscription. Or email your interest to subscriptions@africa-confidential.com or call us on +44 (0)1638 743 633. Offer is based on our 2026 rates and is applicable against all subscription types and pricing tiers.



Related Articles

Paths out of the pandemic

Dire predictions of the toll in Africa from Covid-19 were overblown but disinformation is threatening public health initiatives

Back in March, it was the lull before the storm, with predictions of three million deaths from Covid-19 in Africa. Thankfully, the storm never came. Today, it is...


Kabila's new slim-look cabinet

A cabinet reshuffle brings in a few new faces but fails to find the promised seats for the CNDP

It was supposed to be a reshuffle for austerity, in preparation for next year’s elections, and the government’s heavyweights hold on to their jobs, notably Alexis Thambwé Mwamba...


Negotiating African risk

After underestimating the challenges facing their African investments, Chinese companies are looking for new ways to protect their projects and personnel

'China wholeheartedly welcomed by Africa,’ crowed the state-owned China Daily on 5 March. Yet China’s ever-growing relations with the continent face a complex environment of political and economic...


New names, same games

The new European Commission fails to match the hype about a relaunch of EU-Africa relations

Jean-Claude Juncker waited until his final State of the Union speech in September 2018 to show any interest in EU-Africa relations, surprising many with the offer of a...


How Trump’s tariffs help Beijing in Africa

While Beijing has sharpened its trade offer to the continent, US protectionism has triggered record African imports of Chinese goods

China’s announcement that it will offer tariff-free trade access for all African exporters was a shrewd soft-power move by Beijing – coming just after the United States government...